KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Non-Current Assets (2018 - 2025)

Vir Biotechnology's Other Non-Current Assets history spans 8 years, with the latest figure at $24.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 288.17% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $24.7 million, up 288.17%, while the annual FY2025 figure was $24.7 million, 288.17% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $24.7 million at Vir Biotechnology, up from $16.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $95.2 million in Q2 2025 and bottomed at $5.9 million in Q1 2025.
  • The 5-year median for Other Non-Current Assets is $7.0 million (2021), against an average of $13.4 million.
  • The largest annual shift saw Other Non-Current Assets crashed 55.74% in 2023 before it soared 616.22% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $7.0 million in 2021, then soared by 107.96% to $14.6 million in 2022, then plummeted by 55.74% to $6.4 million in 2023, then dropped by 1.32% to $6.4 million in 2024, then soared by 288.17% to $24.7 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Other Non-Current Assets are $24.7 million (Q4 2025), $16.0 million (Q3 2025), and $95.2 million (Q2 2025).